Wire · opportunities
Beyond Ozempic? New Weight Loss Drug Shows Stunning Results in Major Clinical Trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 October 2026 · Fusion42 review
The investigational drug retatrutide showed substantial weight loss and improved blood sugar control in adults with obesity and type 2 diabetes in an 80-week phase 3 trial, outperforming placebo with up to 18.8% weight loss at the highest dose and better cardiometabolic markers, though gastrointestinal side effects like nausea and diarrhea were more common.
This Wire brief sits within Fusion42's coverage of Longevity & Wellness, Drug Discovery and Biotech, and 4 sources have reported it between 30 Sep 2026 and 13 Oct 2026.
◆ ◆ The Wire takeaway
You face fresh competition as retatrutide raises the bar on combined obesity and diabetes treatment with nearly 20% weight loss. Prepare to reevaluate product positioning or partnerships in metabolic health given this triple agonist’s clinical traction and side effect profile.
◆ Coverage
4 sources · first reported 30 Sep 2026 · latest 13 Oct 2026
◆ Related on Wire
◆ Topics